Wuhan, China

Jianlong Li


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jianlong Li in Antitumor Compounds

Introduction

Jianlong Li is a notable inventor based in Wuhan, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antitumor compounds. His innovative work focuses on enhancing the efficacy of existing treatments while minimizing their side effects.

Latest Patents

Jianlong Li holds a patent for a sulfur-substituted podophyllotoxin derivative, which includes a synthesis method and its applications. This invention introduces a rigid aromatic heterocyclic compound and a sulfonamidated product as substituent groups in the C-ring of podophyllotoxin or 4'-demethylepipodophyllotoxin. The resulting derivative demonstrates significantly increased antitumor activity compared to traditional podophyllotoxin, while also reducing toxic side effects. The experimental results indicate that the compound's antitumor activity is markedly superior to that of its predecessors.

Career Highlights

Jianlong Li is affiliated with Hubei University of Technology, where he continues to advance his research in medicinal chemistry. His work has garnered attention for its potential to improve cancer treatment outcomes. With a focus on innovative synthesis methods, he aims to contribute to the development of more effective therapeutic agents.

Collaborations

Jianlong Li collaborates with Yajie Tang, a fellow researcher, to explore further advancements in the field of antitumor compounds. Their combined expertise enhances the potential for groundbreaking discoveries in medicinal chemistry.

Conclusion

Jianlong Li's innovative work in developing sulfur-substituted podophyllotoxin derivatives represents a significant advancement in cancer treatment. His contributions to the field highlight the importance of ongoing research and innovation in improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…